GemVax Seeks Revival Of Pancreatic Cancer Indication On ASCO Phase III Data
New Phase III pancreatic cancer results for GV1001, an immunotherapeutic peptide, were presented at ASCO, which GemVax hopes will revive the drug after its conditional approval in South Korea was canceled last year.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
South Korea is making a strategic push to strengthen its vaccine capabilities, with a focus on COVID-19 and future pandemics and the aim of becoming a global development hub. But one expert told a recent meeting that these goals should not overshadow the government’s original aim of becoming self-sufficient for the national immunization program.
The International Vaccine Institute’s director general warns about COVID-19 vaccine distribution inequalities and its serious consequences, arguing the case for increased global coordination and responsibility for action to improve the situation.